Cartesian Therapeutics (RNAC) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$143.4 million.
- Cartesian Therapeutics' Enterprise Value rose 3458.7% to -$143.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$143.4 million, marking a year-over-year increase of 3458.7%. This contributed to the annual value of -$212.6 million for FY2024, which is 17643.64% down from last year.
- Per Cartesian Therapeutics' latest filing, its Enterprise Value stood at -$143.4 million for Q3 2025, which was up 3458.7% from -$160.3 million recorded in Q2 2025.
- Cartesian Therapeutics' Enterprise Value's 5-year high stood at -$76.9 million during Q4 2023, with a 5-year trough of -$219.2 million in Q3 2024.
- For the 5-year period, Cartesian Therapeutics' Enterprise Value averaged around -$137.2 million, with its median value being -$138.7 million (2021).
- Per our database at Business Quant, Cartesian Therapeutics' Enterprise Value surged by 4564.2% in 2023 and then tumbled by 17643.64% in 2024.
- Cartesian Therapeutics' Enterprise Value (Quarter) stood at -$128.1 million in 2021, then decreased by 5.11% to -$134.6 million in 2022, then surged by 42.86% to -$76.9 million in 2023, then plummeted by 176.44% to -$212.6 million in 2024, then skyrocketed by 32.56% to -$143.4 million in 2025.
- Its Enterprise Value stands at -$143.4 million for Q3 2025, versus -$160.3 million for Q2 2025 and -$180.4 million for Q1 2025.